NCT03323151 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03323151
Title	A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404)
Acronym	PrE0404
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	PrECOG, LLC.
Indications	mantle cell lymphoma
Therapies	Ibrutinib + Ixazomib
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 14 of 14 entries

Facility	City	State	Zip	Country	Details
Carle Cancer Center	Urbana	Illinois	61801	United States	Details
Georgia Cancer Center at Augusta University	Augusta	Georgia	30912	United States	Details
Gundersen Health System	La Crosse	Wisconsin	54601	United States	Details
Laura and Isaac Perlmutter Cancer Center at NYU	New York	New York	10016	United States	Details
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	United States	Details
ProHealth Care	Waukesha	Wisconsin	53188	United States	Details
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	United States	Details
University of Kansas	Overland Park	Kansas	66210	United States	Details
University of Pennsylvania Abramson Cancer Center	Philadelphia	Pennsylvania	19104	United States	Details
University of Virginia	Charlottesville	Virginia	22908	United States	Details
University of Wisconsin	Madison	Wisconsin	53792	United States	Details
Washington University School of Medicine	Saint Louis	Missouri	63110	United States	Details
West Virginia University	Morgantown	West Virginia	26506	United States	Details
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	United States	Details

Showing 1 to 14 of 14 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03323151Clinical Trial Detail